SCHEMBL3041869

SCHEMBL3041869

CCN(CC1CCCC1)c1cc(F)c(F)cc1C=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A3 P47895 2/20 0.34
GRIA2 P42262 1/20 0.33
GRIN2A Q12879 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
MAPT P10636 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3036495 0.85 GRIA2 (0.38) ALDH1A1L3MBTL1ALDH1A3GRIA2GRIN2A
SCHEMBL3046946 0.85 ALDH1A1 (0.39) ALDH1A1L3MBTL1ALDH1A3GRIA2GRIN2A
SCHEMBL3539336 0.83 NPC1 (0.34) ALDH1A1L3MBTL1ALDH1A3ADH1CADH1A
SCHEMBL3545615 0.83 CNR1 (0.33) ALDH1A1L3MBTL1ALDH1A3ADH1CADH1A
SCHEMBL3041872 0.81 CNR1 (0.40) ALDH1A1L3MBTL1ALDH1A3GRIA2GRIN2A
SCHEMBL3036195 0.80 ERN1 (0.40) ALDH1A1L3MBTL1GRIA2GRIN2AHDAC3
SCHEMBL3043965 0.80 PSEN1 (0.39) ALDH1A1L3MBTL1ALDH1A3MEN1KMT2A
SCHEMBL3043051 0.80 ALDH1A3 (0.40) ALDH1A1L3MBTL1ALDH1A3MAPTNPSR1
SCHEMBL3043756 0.80 ALDH1A3 (0.43) ALDH1A1L3MBTL1ALDH1A3MAPTNPSR1
SCHEMBL3046479 0.79 CSNK1D (0.36) ALDH1A1L3MBTL1ALDH1A3ALDH3A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149563-B9 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-04-22 EP disclosed
EP-2149563-B1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND KOWA CO (JP) 2015-01-07 EP disclosed
US-7659271-B2 Pyrimidine compound having dibenzylamine structure and medicament comprising the same KOWA COMPANY, LTD. (JP) 2010-02-09 US disclosed
EP-2149563-A1 NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND Kowa Company. Ltd. (JP) 2010-02-03 EP disclosed
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) KOWA COMPANY, LTD. (JP) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082352-A1 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) CETP, NPC1L1, MTTP ALDH1A1 4452/4885L3MBTL1 179/4885ALDH1A3 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.